Press Releases

GenomeFrontier Selects BioCina to Manufacture Minicircle and Plasmid DNA for Their CAR-T Cell Therapy Product

17 October 2023 -- Adelaide, Australia -- BioCina Pty, a global end-to-end biologics contract development and manufacturing organisation (CDMO), announced a new partnership with GenomeFrontier Therapeutics the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T) for cancer treatment. BioCina will support GenomeFrontier with process development and GMP manufacturing for Minicircle DNA and Plasmid DNA. GenomeFrontier will leverage their proprietary virus-free cell and gene engineering platforms and Quantum Engine cell-engineering system to manufacture the CAR-T cell therapy for use in a Phase 1 clinical trial.

BioCina’s chief executive officer, Mark W. Womack stated, “We at BioCina are thrilled to be GenomeFrontier’s CDMO partner for this important cancer treatment program, utilising both Minicircle and Plasmid DNA, providing us yet another opportunity to showcase our scientific and technical expertise in support of the CAR-T cell therapy product.”

GenomeFrontier’s founder and CEO/CSO, Sareina Wu said, “We believe that a cancer-free world is not only possible but is more real than ever before, due to major advancements in gene therapy. Therefore, we passionately strive to provide patients with next-generation virus-free gene therapies that are not only advanced and accessible, but also affordable.”


About GenomeFrontier
GenomeFrontier is an innovation-driven therapeutics company focusing on the development of next-generation virus-free gene therapies. Addressing the limitations of current virus-based cell therapies, our IP-protected virus-free Quantum Engine cell engineering and production system enables the establishment of multiplex gene therapies that are efficacious, safe, and cost-effective. Focusing on CAR-T therapies as our first endeavour, Quantum CART (qCART), our first Quantum Engine system, has been successfully established and overcomes most challenges encountered by current autologous CAR-T therapies. Quantum Engine can also be adapted for use with other immune/therapeutic cell types and these systems will be developed in-house or through collaborations.